17:40 – 17:55 Introduction:obesity, weight loss and CV risk Kim Connelly (CAN) 17:55 – 18:10 STEPping forward:cardiovascular risk factors in patients with overweight or obesity
09:15 – 09:20 Overview of oral semaglutide and PIONEER trials Filip K Knop (DNK) 09:20 – 09:30 Case scenarios based on clinical evidence Filip K
17:40 – 17:45 Symposium introduction Jay Skyler 17:45 – 17:55 The legacy and potential of insulin in managing diabetes Stewart Harris 17:55 – 18:15 Using
17:40 – 17:45 The case challengeTeaming up to tackle cardiorenal risk in diabetes Melanie Davies (UK) 17:45 – 17:55 Defining treatment goals: SGLT2i, implications from
Faculty: Carolina Piras De Oliveira (Lilly)Emma Wilmot (UK)Andreas Reichel (GER) Review of key Lyumjev data (including pump data) Patient case sharing by two thought leaders
09:35 – 09:37 Welcome and introduction 09:37 – 09:45 T2D Pathophysiology and GIP and GLP-1 Dual Receptor Agonism 28.09.2021 09:35 – 09:45 Barcelona Hall
17:40 – 17:45 Welcome James Mayjor (Ypsomed AG, AUS) 17:45 – 18:00 What is Android APS Neale Cohen (AUS) 18:00 – 18:10 Published data
Chair: Pierre-Yves Benhamou (FRA) 19:30 – 19:35 Introduction Pierre-Yves Benhamou (FRA) 19:35 – 19:43 Germany: Experience from Germany with DBLG1 w Accu-Chek Insight: point of
